Positive topline results from a 24-week, randomized, double-blind, placebo-controlled, multicenter, phase 2 study of the FGF19 analogue aldafermin (NGM282) in patients with non-alcoholic steatohepatitis

Autor:	Stephen A. Harrison, Guy Neff, Cynthia Guy, Mustafa Bashir, Angelo Paredes, Juan Frias, Ziad H. Younes, James F. Trotter, Nadege T. Gunn, Sam Moussa, Anita Kohli, Kristen Nelson, Mildred Gottwald, William Chang, Andrew Yan, Alex Depaoli, Lei Ling, Hsiao Lieu
Rok vydání:	2020
Předmět:	Hepatology
Zdroj:	Journal of Hepatology. 73:S114-S115
ISSN:	0168-8278
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::c9db2d38c608032c190fc534557f3392 https://doi.org/10.1016/s0168-8278(20)30750-9 Zobrazit plný text záznamu Full Text from ScienceDirect